#1 Clinical Trials Search in Europe

Bendamustine

Bendamustine is a chemotherapy drug that has shown promising results in clinical trials for treating various types of cancer. This article explores the use of bendamustine in clinical trials, focusing on its potential benefits, side effects, and effectiveness in treating different cancers such as lymphomas, leukemias, and solid tumors.

Table of Contents

What is Bendamustine?

Bendamustine is a type of chemotherapy drug used to treat various forms of cancer. It’s also known by several other names, including Treanda, Bendamustine Hydrochloride, Ribomustin, CEP-18083, and SDX-105[7][8]. This medication is approved by the Food and Drug Administration (FDA) for treating certain types of blood cancers, but researchers are also studying its effectiveness in other conditions[8].

How Does Bendamustine Work?

Bendamustine is designed to damage and destroy the DNA of cancer cells, which may cause them to die[7]. It works through several mechanisms, including causing cell death (apoptosis) and interfering with DNA repair, replication, and transcription. This multi-faceted approach makes bendamustine effective against various types of cancer cells[4].

What Conditions Does Bendamustine Treat?

Bendamustine is used to treat several types of cancer, including:

  • Chronic Lymphocytic Leukemia (CLL): A type of blood and bone marrow cancer that affects white blood cells[2][3]
  • Non-Hodgkin’s Lymphoma (NHL): A group of blood cancers that start in the lymphatic system[6]
  • Multiple Myeloma: A cancer of plasma cells, a type of white blood cell[8]
  • Hodgkin’s Lymphoma: A cancer of the lymphatic system[5]

Researchers are also investigating bendamustine’s potential in treating other conditions, such as:

  • Diffuse Large B-Cell Lymphoma (DLBCL): An aggressive type of non-Hodgkin’s lymphoma[1]
  • Acute Lymphoblastic Leukemia/Lymphoma (ALL): A type of blood and bone marrow cancer[7]
  • Ovarian Cancer[4]
  • Small Cell Lung Cancer (SCLC)[9]
  • Soft Tissue Sarcoma: A group of cancers that develop in soft tissues like muscles and fat[10]

How is Bendamustine Administered?

Bendamustine is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The exact dosage and schedule can vary depending on the condition being treated and other factors. Some common administration methods include:

  • 30-60 minute infusions on two consecutive days, repeated every 21-28 days[1][2]
  • Single infusions given once every 3-4 weeks[5]
  • Combination with other drugs, such as rituximab or melphalan[2][8]

Your healthcare team will determine the best dosage and schedule for your specific situation.

Bendamustine in Clinical Trials

Researchers are conducting numerous clinical trials to explore bendamustine’s effectiveness in various cancers and treatment combinations. Some notable studies include:

  • Combining bendamustine with rituximab for treating chronic lymphocytic leukemia and non-Hodgkin’s lymphoma[2][3]
  • Using bendamustine as part of a conditioning regimen before stem cell transplants in multiple myeloma patients[8]
  • Testing bendamustine in older patients with diffuse large B-cell lymphoma[1]
  • Evaluating bendamustine’s effectiveness in relapsed or refractory acute lymphoblastic leukemia/lymphoma[7]

Potential Side Effects

Like all chemotherapy drugs, bendamustine can cause side effects. Some common side effects may include:

  • Fatigue
  • Nausea and vomiting
  • Decreased blood cell counts, which can lead to increased risk of infection, anemia, or bleeding
  • Fever
  • Diarrhea
  • Loss of appetite

Your healthcare team will monitor you closely for side effects and can provide treatments to help manage them. It’s important to report any new symptoms or changes in your health to your doctor promptly[8].

Aspect Details
Cancer Types Studied Non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, multiple myeloma, ovarian cancer, small cell lung cancer, acute lymphoblastic leukemia, soft tissue sarcoma
Administration Method Intravenous infusion, typically over 30-180 minutes
Common Dosage Varies by trial, often 90-120 mg/m² on days 1 and 2 of each cycle
Treatment Cycle Length 21-28 days, depending on the trial
Primary Outcomes Measured Overall response rate, progression-free survival, maximum tolerated dose
Secondary Outcomes Overall survival, toxicity assessment, quality of life
Combination Therapies Often combined with other drugs like rituximab, melphalan, or polatuzumab vedotin
FDA Approval Status Approved for chronic lymphocytic leukemia and some non-Hodgkin’s lymphomas; investigational for other cancers

FAQ

  • What is bendamustine and how does it work? Bendamustine is a chemotherapy drug designed to damage and destroy the DNA of cancer cells, which may cause them to die. It works through several mechanisms, including apoptosis (programmed cell death), DNA repair inhibition, and interference with DNA replication and transcription.
  • What types of cancer is bendamustine being studied for? Clinical trials are investigating bendamustine for various cancers, including non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, ovarian cancer, small cell lung cancer, acute lymphoblastic leukemia, and soft tissue sarcoma.
  • How is bendamustine administered in clinical trials? Bendamustine is typically administered intravenously (through a vein) over 30-180 minutes. The dosage and frequency vary depending on the specific trial and cancer type, but it's often given on days 1 and 2 of each treatment cycle, with cycles repeating every 21-28 days.
  • What are some potential side effects of bendamustine? Common side effects may include low blood cell counts (which can increase the risk of infection, anemia, and bleeding), nausea, fatigue, and loss of appetite. More severe side effects are possible and are closely monitored during clinical trials.
  • Is bendamustine approved for use outside of clinical trials? Yes, bendamustine is FDA-approved for treating chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin's lymphoma. However, its use in other cancers is still being investigated through clinical trials.

Ongoing Clinical Trials on Bendamustine

  • Infusion Study of ARI-0001 Cells for Patients with Resistant or Refractory CD19+ Acute Lymphoid Leukemia

    Recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany The Netherlands Spain

  • Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Italy

  • Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Bulgaria Czechia Denmark France Germany +7

  • Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Greece Italy Spain

Glossary

  • Bendamustine: A chemotherapy drug designed to damage and destroy cancer cell DNA, causing cell death. It's used to treat various types of cancer and is being studied in clinical trials for additional indications.
  • Clinical trial: A research study that tests new medical treatments, interventions, or devices to determine their safety and effectiveness in human participants.
  • Chemotherapy: A type of cancer treatment that uses drugs to destroy cancer cells or stop them from growing and dividing.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without the disease getting worse.
  • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Dose-limiting toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug being tested in a clinical trial.
  • Refractory cancer: Cancer that does not respond to treatment or stops responding after initial improvement.
  • Autologous stem cell transplant: A procedure where a patient's own stem cells are collected, stored, and then reinfused after high-dose chemotherapy to help rebuild the immune system.
  • RECIST criteria: Response Evaluation Criteria In Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.

References

  1. https://clinicaltrials.gov/study/NCT01234467
  2. https://clinicaltrials.gov/study/NCT01131247
  3. https://clinicaltrials.gov/study/NCT01125787
  4. https://clinicaltrials.gov/study/NCT00867503
  5. https://clinicaltrials.gov/study/NCT00705250
  6. https://clinicaltrials.gov/study/NCT00139841
  7. https://clinicaltrials.gov/study/NCT01649622
  8. https://clinicaltrials.gov/study/NCT00916058
  9. https://clinicaltrials.gov/study/NCT00168922
  10. https://clinicaltrials.gov/study/NCT00204620